Eversept Partners LP Makes New $910,000 Investment in InMode Ltd. $INMD

Eversept Partners LP purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 61,938 shares of the healthcare company’s stock, valued at approximately $910,000. Eversept Partners LP owned about 0.10% of InMode at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Cooper Creek Partners Management LLC bought a new stake in shares of InMode during the 3rd quarter worth $14,980,000. Ancient Art L.P. bought a new stake in InMode in the third quarter valued at approximately $14,254,000. Goldman Sachs Group Inc. grew its holdings in InMode by 234.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after acquiring an additional 788,157 shares during the last quarter. Steel Partners Holdings L.P. purchased a new stake in shares of InMode during the fourth quarter worth about $10,352,000. Finally, Doma Perpetual Capital Management LLC grew its position in shares of InMode by 26.8% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,838,431 shares of the healthcare company’s stock worth $42,293,000 after buying an additional 599,108 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird decreased their price target on shares of InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Barclays set a $19.00 target price on shares of InMode and gave the stock an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $16.00.

InMode Stock Performance

NASDAQ:INMD opened at $13.36 on Thursday. The stock has a 50-day simple moving average of $13.91 and a two-hundred day simple moving average of $14.15. The firm has a market capitalization of $846.49 million, a PE ratio of 9.82 and a beta of 1.94. InMode Ltd. has a 52-week low of $12.72 and a 52-week high of $16.74.

InMode (NASDAQ:INMD) last released its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). The firm had revenue of $82.02 million for the quarter, compared to the consensus estimate of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.InMode’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.31 EPS.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.